Protalix BioTherapeutics, Inc. - Common Shares (PLX)

CUSIP: 74365A309

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
+3,718,770
Put/Call ratio
24%
SEC-reported price per share
$2.56
Indexed holders
63
Value change
+$9,615,818
Number of buys
42
Open additional details 1 more signal available
Number of sells
15
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
79,957,519

Security key

74365A309

Report period

Q1 2025

Indexed institutions

63

Top holders

10

Ownership snapshot

Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
31 Dec 2024
3/4/5 13F Highest disclosed value: $5,128,613 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $5.13M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value Top 5
Dexcel Pharma Technologies Ltd. $5.13M
RENAISSANCE TECHNOLOGIES LLC $2.1M
NORTHERN TRUST CORP $1.38M
Eyal Rubin $931.9K
MILLENNIUM MANAGEMENT LLC $729.3K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Dexcel Pharma Technologies Ltd.
3/4/5
10%+ Owner
—
denominator unverified
$5,128,613
3,637,314 shares
— 02 Jun 2021
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$2,101,840
1,118,000 shares
— 31 Dec 2024
NORTHERN TRUST CORP
13F
Company
13F
—
denominator unverified
$1,375,675
731,742 shares
— 31 Dec 2024
Eyal Rubin
3/4/5
Sr. VP and CFO
—
denominator unverified
$931,882
660,909 shares
— 23 Sep 2024
MILLENNIUM MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$729,291
387,921 shares
— 31 Dec 2024
GSA CAPITAL PARTNERS LLP
13F
Company
13F
—
denominator unverified
$575,000
305,749 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
63
Shares
8,186,092
Indexed holders
63
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
46
Q1 2025 indexed holders
63
Indexed holder difference
17
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .